Hikma Pharmaceuticals (HKMPF) Projected to Announce Quarterly Earnings on Thursday

Hikma Pharmaceuticals (OTCMKTS:HKMPF) is expected to post its resultson Thursday, August 6th. Analysts expect Hikma Pharmaceuticals to announce earnings of $1.10 per share and revenue of $1.7030 billion for the quarter.

Hikma Pharmaceuticals Stock Performance

Shares of HKMPF opened at $21.56 on Wednesday. The company’s fifty day moving average is $20.17 and its two-hundred day moving average is $19.44. Hikma Pharmaceuticals has a fifty-two week low of $16.34 and a fifty-two week high of $26.38. The company has a current ratio of 1.82, a quick ratio of 1.06 and a debt-to-equity ratio of 0.57.

Analyst Upgrades and Downgrades

Separately, Citigroup started coverage on Hikma Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold”.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.